China: Weight Management, HMOs, and Ergo Controversies Drive Market Dynamics
Chinese market shifts are evident with Synutra's new meal replacement entry and Nestle's HMO-fortified infant cereal. However, ergothioneine's 'longevity vitamin' claims face scientific scrutiny, posing regulatory risks for novel ingredients.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
China's supplement market is undergoing dynamic shifts, driven by strategic expansions and regulatory challenges. Synutra, a NASDAQ-listed infant formula manufacturer, has leveraged its expertise in dairy proteins to launch a new meal replacement portfolio under its Xianfeng brand, targeting the growing weight management category. This move, showcased at Healthplex Expo 2025 in Shanghai, signals a significant new competitor for existing players in China's rapidly expanding diet and nutrition sector.
Concurrently, Nestle is bolstering its Human Milk Oligosaccharide (HMO) offerings in China with the introduction of its first HMO-fortified infant cereal under the Gerber brand. This rice cereal contains 2'-fucosyllactose (2'-FL), a development directly following the National Health Commission (NHC) approval for 2'-FL's use as an enhancer in cereal-based and canned complementary foods for infants. This regulatory clarity provides a strong commercial signal for brands looking to integrate HMOs into approved infant nutrition formats.
However, the market for novel ingredients faces scrutiny. The amino acid ergothioneine, often marketed as a 'longevity vitamin' with cognitive benefits for the elderly, is under fire from Chinese scientists. Professor Rao Yi publicly questioned ergothioneine's scientific basis and marketing tactics, labelling it a 'quack remedy' on 5th June. Currently, Chinese authorities have not authorised ergothioneine for use in health supplements, presenting significant regulatory hurdles and compliance risks for brands considering its inclusion.
Meanwhile, Barentz, a Dutch ingredients company, is expanding its footprint in the APAC region by acquiring China's Fengli Group. This acquisition, expected to close in late 2025, will deepen Barentz's presence and distribution capabilities within the Chinese market, offering enhanced local service and potentially new ingredient sourcing options for manufacturers.
What this means for China
Manufacturers and brand owners in China face a bifurcated market: established categories see intensified competition and validated ingredient pathways, while novel ingredient adoption requires stringent regulatory diligence. Synutra's entry into weight management will increase price pressure and require existing brands to differentiate through efficacy or channel strategy. Nestle's HMO launch underscores the commercial value of NHC-approved functional ingredients in infant nutrition; brands should expedite R&D for compliant formats. For ingredients like ergothioneine, strong scientific substantiation and explicit NHC approval are non-negotiable to avoid public backlash and regulatory sanctions, impacting product development timelines and investment.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.